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[57] ABSTRACT 
The invention relates to a novel method of administer 
ing the natural female sex hormones, 17 B- estradiol and 
progesterone, to achieve enhanced bioavailability 
thereof. The invention further relates to novel dosage 
forms of 17 [3- estradiol and/or progesterone which are 
adapted for nasal administration, such as solutions, sus 
pensions, gels and ointments. The dosage forms contain 
ing a combination of 17 B-estradiol and progesterone 
are particularly useful as contraceptives, while the dos 
age forms containing only one of the hormonal compo 
nents ?nd utility in the treatment of conditions such as 
menopause, menstrual disorders, etc., which are known 
to respond to administration of a natural or synthetic 
female hormone. 
20 Claims, 5 Drawing Figures 
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METHOD OF ADMINISTERING NATURAL . 
FEMALE SEX HORMONES 
BACKGROUND OF INVENTION 
1. Field of the Invention 
The present invention relates to a novel method of 
5 
administering the natural female sex hormones, 17/3- . 
estradiol and progesterone, and to novel dosage forms 
containing those compounds, singly or in combination, 
which are adapted for nasal administration. 
2. Description of the Prior Art 
l7B-estradiol is the most potent natural estrogen 
found in human beings and is the major secretory prod 
uct of the ovary. It is readily oxidized in the body to 
estrone, which in turn can be hydrated to estriol. These 
transformations take place mainly in the liver, where 
there is free interconversion between estrone and estra 
diol. All three of these natural estrogens are excreted in 
the urine as glucuronides and sulfates, along with ahost 
of related, minor products in water-soluble complexes. 
It is widely known that, following oral administration 
of micronized l7,B-estradiol (E2), the incremental circu 
lation estrogen is principally the less active species es 
trone (E1), which reaches a peak concentration many 
times greater than that of E2. The conversion of E2 to 
E1 and subsequently to other metabolites takes place 
during absorption from the intestine and passage 
through the liver. This extensive metabolism greatly 
limits the oral effectiveness of the natural estrogens and 
their esters. Indeed, because of their limited oral ef? 
cacy, l7B-estradiol and its esters are generally adminis 
tered by intramuscular injection. ' 
Progesterone is the active natural progestin which 
occurs in the corpus luteum, placenta and adrenal cor 
tex. It is not effective by mouth because‘ of its rapid 
'metabolism in the intestinal epithelium and in the liver, 
and is therefore only administered intramuscularly. 
Because of their limited oral effectiveness, these natu 
ral female sex hormones have not found utility in oral 
contraceptives. Instead, only active synthetic estrogens 
and progestins have been prepared and are used for 
contraceptive purposes. The synthetic derivatives have 
also in many cases replaced the natural substances in the 
treatment of menopause, threatened abortion, etc. How 
ever, the synthetic derivatives are, generally speaking, 
much more likely to cause toxic side effects than are the 
relatively safe natural hormones._ 
SUMMARY OF THE INVENTION 
In view of the foregoing, it is apparent that a serious 
need exists for the improved delivery of the natural 
female sex hormones. Thus, it is an object of the present 
invention‘ to provide novel dosage forms and a novel 
method of administering l7B-estradiol and progester 
one, separately or in combination, which will provide 
greatly enhanced bioavailability as compared to oral 
administration, while at the same time providing rela 
tive ease of administration when compared to intramus— 
cular injection. - 
It is a further object of the present invention to pro 
vide a novel contraceptive method and novel composi 
tions for accomplishing same which utilize the natural 
female sex hormones, l7B-estradiol and progesterone, 
and thus avoid'the disadvantages inherent in the use of 
potentially unsafe synthetic estrogens and progestins. 
It is yet a further object of the present invention to 
provide a novel method and novel dosage forms con 
30 
40 
45 
50' 
55 
65 
2 
taining l7B~estradiol or progesterone useful in the treat 
ment of conditions such as menopause, menstrual disor 
ders, etc. which are known to respond to administration 
of a natural or synthetic female sex hormone. 
The foregoing objects are achieved by nasal adminis 
tration of l7B-estradiol (if desired, in the form of one of 
its estrogenically effective esters) and/or progesterone. 
According to the invention, these natural female sex 
hormones are administered via a novel nasal dosage 
form, ‘ i.e., a solution, suspension, ointment or gel 
adapted for nasal administration. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a semi-logarithmic plot of mean blood levels 
of progesterone after intravenous (IV), nasal and in 
traduodenal/ oral (ID) administration of a close of 50 ug 
of progesterone per rat. , r . 
FIG. 2 is a graph showing the area under the curve as‘ 
a function of dose for the intravenous (IV) and nasal 
routes of progesterone administration (50 pg, 100' pg 
and 150 [.tg dosage levels). a 
FIG. 3 is a semi-logarithmic plot of mean blood levels 
of total unconjugated estrogens (TUE) following intra 
venous (IV), nasal and intraduodenal/oral (ID) admin 
istration of a dose of 10 pg of l7B-est‘radiol per rat. 
FIG. 4 is a semi-logarithmic plot of mean blood levels 
of estradiol (E2) following intravenous (IV), nasal and 
intraduodenal/oral (ID) administration of a dose of 10 
pg of l'ZB-estradiol per rat. ' 
7 FIG. 5 is a semi-logarithmic plotof mean blood levels 
, of estrone (E1 ) following intravenous (IV), nasal and 
intraduodenal/oral (ID) administration of a dose of 10 
pg of V17B~estradiol per rat. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The word “progesterone” as used herein means 
pregn-4-ene-3,20-dione, i.e., the compound of the for 
mula - 
CH 3 
CO 
O 
and is intended to include progesterone derived from 
natural sources as well as that made synthetically. 
The word ‘.‘l7B-estradiol" as used herein is intended 
to encompass any pharmaceutically acceptable, estro 
genically active form of l7B-estradiol, i.e., estra 
1,3,5(10)-triene-3,l7B-diol itself, which has the formula 
HO 
4,315,925 
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and which may‘ be extracted from natural sources or 
made synthetically, or one of its >3-_,or l7-monoesters or 
3,'l7-dies_tlers. Byway of illustration, suitable esters of 
17,8-est‘ra‘diol for purposes of the present invention in 
clude 3-monoesters such as estradiol benzoate and'estra 
diol 3-ace'tate; l7v-monoesters such as estradiol cypio 
nate,_estradi_ol l7épropionate,estrad‘iol ljv-aceta'te, estra 
diol' 17-'heptanoatev (estradiol enanthate), estradiol 1'] 
undecanoate (elstradiolundecylat‘e) and estradiol l7-_val 
erate; and 3,17-‘di'est‘ers such 
and estradiol diacetatelp ' ' I _ A . 
According to the present invention, it has surpris 
ingly been found; that 17,8-estradiol and progesterone 
can be administered nasally with results considerably 
superior to those obtained 1with ioraladministration. The 
following'studies' were unde’r'tak'e'n'i’to examine the bi 
oavailability of progesterone and 17B-estradiol from 
nasal solution in comparison with‘ the bioavailability of 
these drugs when administered‘ orally' and‘ intrave 
nously. ' ' ‘ ' - ‘ 
'Sprague-Dawley' male rats,‘- each weighing about 270 
grams, were used in the progesterone study; For nasal 
administration, the rats"were"anesthetized us'irigsodium 
pentobarbital (50 mg/kg) an'd<the< drug was‘adrninis 
tered to thenasal cavity byrmeans ofia' micropip'et at 
dosage levels of 50 pg, "100 pg and .1-50 pg/rat of [4 
14C]-pr0gesterone- (.~8.51pCi/rat) in 0.1 ml of isotonic 
saline-containing l—,2%. Tween" 80 as ‘a 'solubilizing 
agent, according to the procedure described by Hirai-et 
al, the 98th Annual Meeting of Pharmaceutical Society 
of Japan, Okayama, April 1978,.except that the ‘end of 
the tube leading from the esophagus _-to the nasal cavity 
.was closed and the drug was administered to the nostrils 
which were then closed with anadhesive agent. For 
oral (intraduodenal) administration, the rats were anes 
thetized and the abdomen: of ‘each rat" wasl-opened 
through a midline incision1'and‘a‘50 pg/rat dose of the 
d_rug;([4-14C]—progesterone in 01ml isotonic saline with 
l'—2% Tween 80)__,Was .injected'idirecitly through the 
duodenum. For intravenous administration, the) rats 
were anesthetized and the drug was injected through 
the femoral vein at dosage levels of 50 pg, 100 pg and 
150 pg/rat of [4"-l4C]-progesterone in 0.1 ml of isotonic 
saline containing l—2% Tween 80. Blood was sampled 
periodically from the femoral aorta after IV and nasal 
administration, and lifrorn the tail vein after ID adminis 
tration. Blood levels of progesterone were determined 
by thin layer ch'romotograph-y. . 
FIG. 1 shows the mean blood levels of progesterone 
for the study described above after intravenous, nasal 
and oral administration of a dose of 50 pg/rat, while 
Table I below summarizes the area under the curve for 
the three-routes of administration-at the various doses. 
‘ ‘ ‘TABLET’ " ‘ _ ' 
AREA UNDER THE CURVE AFTER INTRAVENOUS, 
' NASAL AND INTRAoUopENAL , ADMINISTRATIO  OF PROGESTE'RONE IN RATS ‘ 
as est’radiol dipropionate 
Dose ~ AUC()°° , nigilmiin/ml ‘- Nasal ‘ 1D 
pg/rat 1V Nasal ID IV [V 
50 1612.2“ 1659.0 19.0 1.029 0.012 
i808 i 109.2 1114.6 
100 3520.0 3599.0 — 1.022 — 
i491.0 . i62l.4 
150 4480.2 4798.9 — 1,071 — 
i4604 ~i1885 
‘mean t SE(r1 : 4-6). 
By using the two tailed t-test, it canbe shown that the 
area under the curve following intravenous and nasal 
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administration at each dosage were not significantly 
different, even at the 0.001 level. However, as can be 
seen from Table’ I,‘ oral administration vof 50 pg resulted 
in bioavailability equal to only ‘1.2% that of an equiva 
lent dose given ‘intravenously. Also from Table I, it can 
be seen that the nasal bioavailability of progesterone at 
the 50 pg dosage level was 85.75 times greater than the 
oral bioavailability. 1 - ~ 
. ': It can also be seen from FIG. 1 that progesterone is 
very rapidly absorbed from the nasal mucosa; thus, at 
the 50 pg dosage level, the peak plasma level was at 
tained in less than 7 minutes after instillation of the nose 
drops. ‘ 
_ FIG. 2 shows the area under the curve as a function 
of dose for the intravenous and nasal routes. As can be 
seen from FIG. 2, for both IV and nasal routes of ad 
ministration the area under the curve (AUC) was di 
rectly proportional to the dose administered. 
' The'study described above indicates that progester 
one is rapidly absorbed from the nasal mucosa into the 
systemic :circulation without first pass metabolism. It is 
further apparent from this study that the bioavailability 
of progesterone when administered nasally is equivalent 
to, the bioavailability of the drug where administered 
intravenously and vastly superior to'its bioavailability 
by the oral route. " 
(A study similar to ‘that described above was under 
taken to' study the bioavailability of nasally adminis 
tered 17,8-estradiol vis-a-vis its bioavailability via intra 
venous and ‘oral routes. Sprague-Dawley male rats, 
each weighing approximately 270 grams, were given 
dosages of 5 pg, 10 pg and 20 pg/rat of [6,7-3H] 17B 
estradiol in 0.1 in] isotonic saline containing 1% Tween 
80 via the intravenous, nasal and intraduodenal routes, 
according to the procedures described above with re 
spect to ,the progesterone study. Blood samples were 
taken periodically as described in the progesterone 
Studyand assayed for estradiol (E2), estrone (E1) and 
total ,unconjugated estrogens (TUE). 
FIGS. 3, 4 and 5 show typical plots ofthe mean blood 
levels-of TUE, E2 and E1 following intravenous, nasal 
and ‘oral administration of 10 pg of l7B-estradiol per 
rat. .These ?gures clearly show that l7B-estradiol is 
rapidly absorbed by the nasal mucosa. 
Table II below shows the area under the curve for the 
three routes of administration at the various dosage 
levels of 17,3-estradiol. 
TABLE II 
AREA UNDER THE CURVE AND BIOAVAILABILITY 
. , ,.OF TUE, ‘E; AND E1 FOR THE DIFFERENT ROUTES 
OF ADIMINISTRATION AT THE VARIOUS DOSES 
DOSE ROU'I‘EOF AUCQ‘”, NG. MIN. Mr‘ 
pG/RAT ADMINISTRATION I TUE E2 E1 
5 IV 555.5 290.8 53.4 
. .NASAL v337.0 146.8 33.5 
, »_ (0.606) (0.505) (1.657) 
' ORAL 119.2 11.1 10.6 
(0.215) (0.032) (0.199) 
'10- -Iv 954.6 609.0 83.5 
NASAL 761.2 ‘415.2 173.1 
. - (0.797) (0.682) (2.073) 
.ORAL 314.2 19.1 16.8 
v ‘ (0.329) (0.031) (0.201) 
20 Iv 1936.9 1062.6 164.4 
1 \ NASAL“' 1777.2 891.8 354.0 
: (0.918) (0.839) (2.153) 
.1 ORAL 786.9 53.4 42.4 
4,315,925 
5 
TABLE ll-continued 
AREA UNDER THE CURVE AND BIOAVAILABILITY 
OF TUE, E; AND E] FOR THE DIFFERENT ROUTES 
OF ADIMINISTRATION AT THEIVARIOUS DOSES 
DOSE ROUTE OF AUCQ°°,NG. MIN. ML-l 
uG/RAT ADMINISTRATION, TUE E2 13] 
(0.400) (0.050) (0.258) 
()RATlO VS. 1V 
As can be seen from Table II, the TUE bioavailability 
after nasal administration ranged from 60.6% to 91.8% 
that of the corresponding doses given intravenously, 
while oral administration resulted in TUE bioavailabil 
ity that ranged from only 21.5% to 40.6% that of the 
corresponding doses given intravenously. Thus, nasal 
bioavailability of TUE was from 2.26 to 2.83 times 
greater than oral bioavailability. Even more signi? 
cantly, Table II further shows that the E2 bioavailability 
after nasal administration ranged from 50.5% to 83.9% 
that of the corresponding doses given intravenously, 
while oral administration resulted in E2 bioavailabilities 
that ranged from only 3.1% to 5.0% that of the corre 
sponding doses given intravenously. Thus, nasal bi 
oavailability of E2 was from 13.23 to 21.74 times greater 
than oral bioavailability. 
The studies described above indicate that progester 
one and 17 B-estradiol are rapidly absorbed from the 
nasal mucosa into systemic blood without extensive 
intestinal or ?rst pass metabolism. 
Progesterone and 17,8-estradiol can be conveniently 
administered nasally to warm-blooded animals by for 
mulating them, singly or in combination, into a nasal 
dosage form comprising the selected natural female sex 
hormone(s) and a nontoxic pharmaceutically acceptable 
nasal carrier therefor. As indicated earlier, any pharma 
ceutically acceptable, estrogenically active form of 
l'lB-estradiol can be employed in the nasal form, e.g., 
the'diol itself or one of its esters. In a preferred embodi 
ment of the invention, both progesterone and a suitable 
form of 17/3-estradiol are present in the nasal dosage 
form, which can be employed in preventing conception, 
for example, by administration in a cyclic manner anala 
gous to that used for the oral contraceptives. 
In another embodiment, the estrogenic component, 
i.e., one of the suitable forms of l7B-estradiol, is present 
but progesterone is not; this type of composition may be 
used for any of a variety of conditions for which natural 
or synthetic estrogens have previously been adminis 
tered, e. g., to control menopausal symptoms, hot flushes 
and later osteoporosis; also in atropic vaginitis, and to 
relieve postpartum breast engorgement, dysmenorrhea, 
amenorrhea, menorrhagia, and as substitution therapy 
in ovarian dwar?sm; also to control prostatic carci 
noma, and possibly also as a “morning-after” contracep 
tive. Also, the “estrogen only” nasal composition could 
be used in a sequential contraceptive regimen in which 
estrogen alone is to be administered for a part of the 
cycle. '‘ 
In another embodiment of the present invention, pro 
gesterone is present in the nasal dosage form, but the 
estrogenic component is not. This type of composition 
may be used in the treatment of conditions for which 
natural or synthetic progestins have previously been 
used, e. g., in threatened or habitual abortion, endometri 
osis and menstrual disorders such as dysmenorrhea and 
functional uterine bleeding, in inhibiting ovulation and 
possibly as a “progestin only" continuously adminis 
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tered contraceptive (analogous to “minipill" type of 
oral contraceptives). 
Suitable nontoxic pharmaceutically acceptable nasal 
carriers for use in the compositions of the present inven 
tion will be apparent to those skilled in the art of nasal 
pharmaceutical formulations. For those not skilled in 
the art, reference is made'to the text entitled “REM 
INGTON’S PHARMACEUTICAL SCIENCES”, 4th 
edition, 1970. Obviously, the choice of suitable carriers 
will depend on the exact nature of the particular nasal 
dosage form desired, e.g. whether the active in 
gredient(s) is/are to be formulated into a nasal solution 
(for use as drops or as a spray), a nasal suspension, a 
nasal ointment or a nasal gel, as well as on the identity 
of the active ingredient(s). Preferred nasal dosage forms 
are solutions, suspensions and gels, which contain a 
major amount of water (preferably puri?ed water) in 
addition to the active ingredient(s). Minor amounts of 
other ingredients such as pH adjusters (e.g., a base such 
as NaOH), emulsi?ers or dispersing agents (e.g. poly 
oxyethylene 20 sorbitan mono-oleate), buffering agents, 
preservatives, wetting agents and jelling agents (e.g. 
methylcellulose) may also be present. Also, a sustained 
release composition, e.g. sustained release gel, readily 
can be prepared by employing l7B-estradiol in one of its 
relatively insoluble, long-acting forms, e.g. as estradiol 
cypionate. 
Examples of the preparation of typical nasal composi: 
tions are set forth below. However, it is to be underi 
stood that these examples are given by way of illustra 
tion only and are not to be construed as limiting the 
invention either in spirit or in scope as many modi?ca 
tions both in materials and in methods will be apparent 
to those skilled in the art. 
EXAMPLE 1 
25 milligrams of progesterone and 5v milligrams of 
17,8-estradiol were combined with 10 milligrams of 
Tween 80. That mixture was then combined. with a 
quantity of isotonic saline suf?cient to bring the total 
volume to 50 milliliters. The solution was sterilized by 
being passed through a 0.2 micron Millipore ?lter. 
EXAMPLE 2 
50 milligrams of progesterone and 5 milligrams of 17 
B-estradiol were combined with 10 milligrams of 
Tween 80. That mixture was then combined with a 
quantity of isotonic" saline sufficient to bring the total 
volume of the solution to 50 milliliters. The solution was 
sterilized by being passed through a 0.2 micron Mil 
lipore ?lter. 
EXAMPLE 3 
250 milliliters of isotonic saline were heated to 80° C. 
and 1.50 grams of Methocel were added, with stirring. 
The resultant mixture was allowed to stand at room 
temperature for 2 hours. Then, 50 milligrams of proges 
terone and 10 milligrams of l7B-estradiol were mixed 
together with 10 milligrams of Tween 80. The steroid/ 
Tween mixture and a quantity of isotonic salinersuf? 
cient to bring the total 'volume to 500 milliliters were 
added to the gel and thoroughly mixed. 
EXAMPLE 4 
Repetition of the procedure of Example 1, but omit 
ting the 25 milligrams of progesterone, affords an “es 
trogen only” nasal composition. 
4,315,925 
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EXAMPLE 5 
Repetition of the procedure of Example 2, but omit 
ting the 5 milligrams of l7B-estradiol, affords a “proges 
terone only” nasal composition. 
EXAMPLE 6 
Substitution of an equivalent quantity of estradiol 
benzoate, estradiol cypionate, estradiol dipropionate, 
estradiol enanthate or estradiol l7-valerate for the 17,8 
estradiol employed in Example 1, 2, 3 or 4 and repeti 
tion of the procedures there detailed affords other nasal 
compositions according to the invention. 
Naturally, the therapeutic dosage range for nasal 
administration of the compositions of the present inven 
tion will vary with the size of the patient, the condition 
for which the composition is administered and the par 
ticular form of l7B-estradiol employed (when the com 
position is an “estrogen only” or estrogen/progestin 
combination). A typical dose ofa combination form for 
use as a contraceptive would be from 10 pg to 500 pg of 
17/3-estradiol and from 10 pg to 5000 pg of progester 
one, administered nasally once daily. The quantity of 
nasal dosage form needed to deliver the desired dose 
will of course depend on ‘the concentration of the active 
ingredients in the composition. For example, when a 
composition as described in Example 2 above is used to 
deliver a typical dose of 0.5 mg of progesterone, the 
volume of solution which would be needed would be 
approximately 0.5 ml. 
While the invention has been described in terms of 
various preferred embodiments, the skilled artisan will 
appreciate that various modi?cations, substitutions, 
omissions and additions may be made without departing 
from the spirit thereof. Accordingly, it is intended that 
the scope of the present invention be limited solely by 
the scope of the following claims. 
What is claimed is: 
1. A method of mammalian contraception which 
comprises nasally administering to a female mammal a 
contraceptively effective amount of a combination of 
progesterone and a pharmaceutically acceptable, estro 
genically active form of 17,8-estradiol. 
2. A method of eliciting a progestational response in 
a mammal which comprises nasally administering 
thereto a progestationally effective amount of proges 
terone. 
3. A method of eliciting an estrogenic response in a 
mammal which comprises nasally administering thereto 
an estrogenically effective amount of a pharmaceuti 
cally acceptable, estrogenically active form of 178 
estradiol. 
4. A method of mammalian contraception according 
to claim 1 which comprises nasally administering to a 
female mammal a pharmaceutically acceptable nasal 
dosage form which comprises a contraceptively effec 
tive amount of a combination of progesterone and a 
O 
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pharmaceutically acceptable, estrogenically active form 
of l7B-estradiol, together with a nontoxic pharmaceuti 
cally acceptable nasal carrier therefor. 
5. A method according to claim 2 for eliciting a pro 
gestational response in a mammal which comprises 
nasally administering thereto a pharmaceutically ac 
ceptable nasal dosage form which comprises a progesta 
tionally effective amount of progesterone and a non 
toxic pharmaceutically acceptable nasal carrier there 
for. 
6. A method according to claim 3 for eliciting an 
estrogenic response in a mammal which comprises na 
sally administering thereto a pharmaceutically accept 
able nasal dosage form which comprises an estrogeni 
cally effective amount of a pharmaceutically accept 
able, estrogenically active form of l7B-estradiol and a 
nontoxic pharmaceutically acceptable nasal carrier 
therefor. 
7. A method according to claim 1, 3, 4 or 6 wherein 
the pharmaceutically acceptable, estrogenically active 
form of 17B-estradiol is selected from the group consist 
ing of 17,8-estradiol, 3~monoesters of 17,8-estradiol, 
l7-monoesters of l7B-estradiol and 3,17-diesters of 17,8 
estradiol. 
8. A method according to claim 7 wherein the phar 
maceutically acceptable, estrogenically active form of 
l7B-estradiol is l7B-estradiol. 
9. A method according to claim 7 wherein the phar 
maceutically acceptable, estrogenically active form of 
17,8-estradiol is estradiol benzoate. 
10. A method according to claim 7 wherein the phar 
maceutically acceptable, estrogenically active form of 
17,8-estradiol is estradiol cypionate. 
11. A method according to claim 7 wherein the phar 
maceutically acceptable, estrogenically active form of 
l7B-estradiol is estradiol dipropionate. 
12. A method according to claim 7 wherein the phar 
maceutically acceptable, estrogenically active form of 
l7B-estradiol is estradiol enanthate. 
13. A method according to claim 7 wherein the phar 
maceutically acceptable, estrogenically active form of 
l7B-estradiol is estradiol l7-valerate. 
14. A method according to claim 4, 5 or 6 wherein 
said dosage form is a nasal solution. 
15. A method according to claim 4, 5 or 6 wherein 
said dosage form is a nasal suspension. 
16. A method according to claim 4, 5 or 6 wherein 
said dosage form is a nasal ointment. 
17. A method according to claim 4, 5 or 6 wherein 
said dosage form is a nasal gel. 
18. A method according to claim 4 or 6 wherein said 
dosage form is a sustained release nasal dosage form. 
19. A method according to claim 4 or 6 wherein said 
dosage form is a sustained release nasal gel. 
20. A method according to claim 4, 5 or 6 wherein 
said dosage form is isotonic. 
* * * * >l< 
